Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcomein advanced estrogen receptor (ER)-positive breast cancer, however relapse isinevitable. Human breast cancer cell lines
Additional file 1: Table S2. Sequences of shRNA&siRNA against specific target in this study. Fig. S1 A Colony formation assay of sunitinib-resistant cell lines and control cell lines with DMSO in 12-w
Background: We investigated whether multiparametric magnetic resonance imaging (mpMRI) could identify activity of PT2385, a novel inhibitor of hypoxia inducible factor-2 (HIF-2), in patients with adva
Sunitinib is a TKI inhibitor used for managing metastatic renal cell carcinoma (RCC). However, chronic sunitinib treatment in RCC usually results in the development of drug resistance via alternating
Although sunitinib contributes to prolonging the progression-free survival of metastatic renal cell carcinoma significantly, the universal presence of resistance limits the initial response rate and r